Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | FDPS | P14324 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150675 | 1.00 | EPHX2 (0.56) | EPHX2FDPSALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL145872 | 0.85 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2KDM4EGAAABCG2 | |
| SCHEMBL145871 | 0.85 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2KDM4EGAAABCG2 | |
| SCHEMBL1881669 | 0.83 | ABCG2 (0.66) | EPHX2FDPSALDH1A1SMN1; SMN2ABCG2 | |
| SCHEMBL1881666 | 0.83 | ABCG2 (0.66) | EPHX2FDPSALDH1A1SMN1; SMN2ABCG2 | |
| SCHEMBL8694346 | 0.81 | EPHX2 (0.51) | EPHX2FDPSALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL23134034 | 0.81 | MAOA (0.52) | EPHX2FDPSALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1854594 | 0.81 | TTR (0.46) | EPHX2FDPSALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1854592 | 0.81 | TTR (0.46) | EPHX2FDPSALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL19504304 | 0.80 | ALOX5 (0.55) | EPHX2FDPSALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107252429-B | Novel anti-inflammatory agent | 雷斯韦洛吉克斯公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-3431086-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2020-06-17 | — | — | EP | disclosed |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2020-04-30 | — | — | US | disclosed |
| EP-3431086-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | Resverlogix Corp. (CA) | 2019-01-23 | — | — | EP | disclosed |
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | disclosed |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2017-11-23 | — | — | US | disclosed |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2017-11-16 | — | — | US | disclosed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | disclosed |
| WO-2013186612-A1 | THE USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BET (BROMODOMAIN AND EXTRA TERMINAL DOMAIN) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-12-19 | — | — | WO | disclosed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | disclosed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | EPHX2 3730/4885FDPS 2215/4885ALDH1A1 1042/4885 |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | EPHX2 4067/4885FDPS 3972/4885ALDH1A1 3920/4885 |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | EPHX2 3730/4885FDPS 2215/4885ALDH1A1 1042/4885 |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | EPHX2 3730/4885FDPS 2215/4885ALDH1A1 1042/4885 |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | EPHX2 3730/4885FDPS 2215/4885ALDH1A1 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.